An experiment conducted on CD44+ prostate cancer stem cells provided relevant information that apigenin co-administrated with cisplatin stimulated the therapeutic effects of cisplatin by inducing a series of modulatory effects on the expression of essential proteins and enzymes [188]. Here, CD44 is linked to prostate cancer.